0001209191-22-017046.txt : 20220308
0001209191-22-017046.hdr.sgml : 20220308
20220308160749
ACCESSION NUMBER: 0001209191-22-017046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220304
FILED AS OF DATE: 20220308
DATE AS OF CHANGE: 20220308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fridriksdottir Hafrun
CENTRAL INDEX KEY: 0001561458
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16174
FILM NUMBER: 22721782
MAIL ADDRESS:
STREET 1: 400 INTERPACE PARKWAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000818686
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 BAZEL ST
STREET 2: P O B 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 49131
BUSINESS PHONE: 9729267267
MAIL ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 5 BAZEL ST PO B 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 49131
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-04
0
0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
0001561458
Fridriksdottir Hafrun
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV
L3
6944020
ISRAEL
0
1
0
0
Executive VP, Global R&D
Ordinary Shares
2022-03-04
4
M
0
51488
A
116996.514
D
Ordinary Shares
2022-03-04
4
S
0
18020
7.4825
D
98976.514
D
Ordinary Shares
2022-03-04
4
M
0
18905
A
117881.514
D
Ordinary Shares
2022-03-04
4
S
0
6618
7.4825
D
111263.514
D
Ordinary Shares
2022-03-05
4
M
0
23764
A
135027.514
D
Ordinary Shares
2022-03-07
4
S
0
8941
7.3667
D
126086.514
D
Restricted Share Units
2022-03-04
4
M
0
51488
0.00
D
Ordinary Shares
51488
0
D
Restricted Share Units
2022-03-04
4
M
0
18905
0.00
D
Ordinary Shares
18905
18906
D
Restricted Share Units
2022-03-04
4
A
0
140750
0.00
A
Ordinary Shares
140750
140750
D
Restricted Share Units
2022-03-05
4
M
0
23764
0.00
D
Ordinary Shares
23764
71293
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting
of the restricted share units listed in Table II.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.
Restricted share units were granted on March 4, 2019, with 18,905 having vested on each of March 4, 2021 and March 4, 2022, and 18,906 vesting on March 4, 2023.
Restricted share units were granted on March 4, 2022, with 35,187 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 35,189
vesting on March 4, 2026.
Restricted share units were granted on March 5, 2021, with 23,764 having vested on March 5, 2022, 23,764 vesting on each of March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025.
/s/ Dov Bergwerk as attorney-in-fact for Hafrun Fridriksdottir
2022-03-08